Zymeworks has delivered a very strong share price run over the past few years, and the recent licensing deal activity has sharpened the question of what investors are really paying for today. With the stock now reflecting both past gains and fresh expectations, the core issue is how that market value lines up against the company’s book value. Over the past 3 years, Zymeworks has produced a share price gain of roughly 3x. This puts a lot of history and optimism on the line when you compare...
Zymeworks (ZYME) has drawn fresh attention after two October announcements: new Phase 1 data for its antibody drug conjugate ZW191 in ovarian cancer, and a wide-ranging licensing deal with Roche for trispecific candidate ZW209. Those catalysts have arrived after a period of strong momentum, with Zymeworks’ share price delivering a 19.8% 1 month return and 28.2% 3 month return, while total shareholder return over the past year is 65.9% and roughly 4x over three years. Scan other high-momentum...
Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.
Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phase 1 Zymeworks ovarian cancer data show strong anti-tumor activity for ZW191 in heavily pretreated patients. Read more here.
Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr
Zymeworks (ZYME) said late Wednesday it completed its previously announced $929 million acquisition
Zymeworks Inc. remains a Buy, leveraging validated technology, strong price momentum, and upcoming catalysts. Read more on ZYME stock here.
Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.